Benefits
Cardiovascular use in TCM and Chinese hospital practice
Most-used TCM herb for cardiovascular conditions over 2,000 years. Widely used in Chinese hospitals as IV preparations (Danhong, Salvianolate, Compound Danshen) for acute angina, MI, stroke. Hundreds of Chinese RCTs reported but methodological quality concerns: poor blinding, short duration, weak control conditions, language barriers. Mechanism robust (vasodilation, antiplatelet, antioxidant); clinical translation to oral Western use has been mixed.
Compound Danshen Dropping Pill (CDDP) for stable angina
CDDP — combination of Salvia miltiorrhiza + Panax notoginseng + Borneol — has multiple Chinese RCTs for stable angina pectoris suggesting symptomatic improvement. 2025 review summarized RCT evidence with general support for symptom relief, though methodological concerns persist. Not widely available/marketed in Western markets but established as multi-million-dollar Chinese pharmaceutical product.
Negative Western trial in hypertension/dyslipidemia (Van Poppel 2015)
A Dutch double-blind randomized crossover trial used Salvia miltiorrhiza root water-extract (3 g/day for 4 weeks) in patients with hypertension and hyperlipidemia. Result: NO beneficial effect on cardiovascular risk factors, with no significant reduction in BP, lipids, or other markers vs placebo. Important Western counterevidence to enthusiastic Chinese trial results, suggesting effects may depend on preparation type, population, formulation, or other factors not isolated in monotherapy oral testing.
In vitro and animal mechanistic support
Tanshinone IIA and salvianolic acids robustly demonstrate: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity, anticoagulant effects, mitochondrial protection, free radical scavenging. Mechanistic basis is strong; clinical translation is the gap. Used as research compound in cardiovascular preclinical models extensively.
Antiplatelet activity (relevant to traditional 'blood-moving' uses)
Tanshinones inhibit platelet aggregation in vitro and in animal models — mechanistic basis for traditional 'blood-moving' (huo xue) classification. Clinically important because this mechanism explains the documented warfarin INR elevation interactions — a real concern for safety in patients on anticoagulants.
Mechanism of action
ACE inhibition and angiotensin II reduction
Salvia miltiorrhiza components inhibit angiotensin converting enzyme (ACE), reducing angiotensin II levels and indirectly affecting atrial natriuretic peptide. Mechanism comparable to (but weaker than) pharmaceutical ACE inhibitors. Provides theoretical basis for cardiovascular protection — though oral monotherapy effect size in Western trials has been modest at best.
Vasodilation via nitric oxide and calcium channel modulation
Tanshinones produce vasodilation via multiple mechanisms: NO synthesis enhancement, calcium channel modulation, smooth muscle relaxation. Improves coronary blood flow in animal models and in vitro. Underlies traditional applications for chest pain, stroke recovery, peripheral vascular conditions.
Antiplatelet effects via thromboxane reduction
Tanshinones inhibit platelet aggregation by reducing thromboxane A2 production and modulating COX-1 pathway. Mechanism comparable to aspirin but typically weaker. Clinically important for both traditional 'blood-moving' indication and for warfarin interaction concerns.
Antioxidant and anti-inflammatory pleiotropic effects
Salvianolic acids increase SOD, catalase, GPx, GSH levels; reduce lipid peroxidation and inflammatory cytokines. Combined antioxidant + anti-inflammatory effects relevant to ischemia-reperfusion injury (the rationale for IV use in acute MI/stroke in Chinese hospitals). Mechanism strong; standalone oral consumer product effect size unclear.
Clinical trials
Randomized double-blind cross-over trial (van Poppel PCM, Breedveld P, Abbink EJ, Roelofs H, van Heerde W, Smits P, Lin W, Tan AHA, Russel FG, Donders R, Tack CJ, Rongen GA 2015, PLoS One 10(6):e0128695, doi:10.1371/journal.pone.0128695). NCT01563770.
Patients with hypertension and hyperlipidemia (ages 40-70). Randomized to 3 capsules of 500 mg Salvia miltiorrhiza extract twice daily (3 g/day) OR placebo for 4 weeks each in crossover design. Endpoints: lipid profile, BP, endothelial function, oxidative stress, inflammation, hemostasis, insulin sensitivity.
NO beneficial effect on cardiovascular risk factors. No significant changes in lipid profile, BP, endothelial function, or other CV risk markers vs placebo. Authors concluded: 'Salvia miltiorrhiza root water-extract has no beneficial effect on cardiovascular risk factors.' Important Western counterevidence to Chinese trials. Authors noted: quality of Chinese clinical trials of Danshen is poor; not easily accessible to Western physicians as most published in Chinese — explanation for evidence base disconnect.
Review (Wei 2025, related publications).
Reviews of multiple Chinese clinical trials of Compound Danshen Dropping Pill (Salvia miltiorrhiza + Panax notoginseng + Borneol) for stable angina pectoris. Comparator: standard pharmacological treatments (nitrates, beta-blockers, calcium channel blockers).
CDDP demonstrated symptomatic improvement in angina pectoris in multiple Chinese clinical trials — though most have methodological limitations (blinding concerns, short duration, weak controls). Establishes clinical use case for combination Danshen formulas rather than monotherapy. Notable: traditional Chinese use is almost always in combination — Western monotherapy testing may not reflect optimal use.
Comprehensive pharmacology review (Adams JD, Wang R, Yang J, Lien EJ 2006, Chin Med 1:3, doi:10.1186/1749-8546-1-3).
Review of preclinical and clinical examinations of Salvia miltiorrhiza and tanshinones in ischemic conditions including angina, heart attack, stroke.
Documented robust preclinical evidence for: ACE inhibition, vasodilation, antiplatelet activity, anti-inflammatory effects, antioxidant capacity. Clinical evidence assessed across preparation types, doses, blinding, controls. Authors noted methodological limitations of available trials and emphasized need for more rigorous Western-standard clinical trials. Established the central tension in danshen evidence: strong mechanism + traditional use vs limited rigorous modern trial validation.